Comparative Pharmacology
Head-to-head clinical analysis: ANGIOVIST 292 versus GADOTERIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOVIST 292 versus GADOTERIDOL.
ANGIOVIST 292 vs GADOTERIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiovist 292 (diatrizoate meglumine and diatrizoate sodium) is an ionic, high-osmolar iodinated contrast agent. It functions by absorbing x-rays due to the high atomic number of iodine, thereby enhancing the radiopacity of vascular structures and organs during diagnostic imaging. It also increases the osmolarity of the intravascular compartment, which can lead to hemodynamic effects.
Gadoteridol is a paramagnetic gadolinium-based contrast agent that increases signal intensity in T1-weighted magnetic resonance imaging by shortening the T1 relaxation time of protons in water molecules. It distributes in the extracellular fluid compartment and does not cross the intact blood-brain barrier, thus enhancing imaging in areas of disrupted barrier or abnormal vascularity.
Intravenous administration: 50-150 mL of a 292 mg iodine/mL solution for adults, depending on the imaging procedure, with a maximum total dose of 300 mL per procedure.
0.2 mL/kg (0.1 mmol/kg) IV bolus, max 20 mL per dose; additional doses up to 0.4 mL/kg may be given within 30 minutes if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; prolonged to >30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life 1.5-2 hours in normal renal function; prolonged to 10-18 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 30 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal; >90% of dose excreted unchanged in urine within 24 hours. Fecal excretion is negligible (<1%).
Renal: >95% unchanged via glomerular filtration. Biliary/fecal: <5%.
Category C
Category C
Contrast Agent
Contrast Agent